HYNES CONVENTION CENTER

Boston, Massachusetts
March 4–7, 2018

 

CROI 2017 Categories and Definitions

CROI 2017 Categories And Definitions
Categories may be modified from year to year.
Note: All studies of infants, children, or adolescents should be submitted to category (S) Pediatrics and Adolescents.
All resistance studies and trials should be submitted in category (J) HIV Drug Resistance.
All studies of Hepatitis (including A, B, C, and E in monoinfection or HIV coinfection) should be submitted under category (L) Hepatitis Viruses and Liver Complications.

Category

Definition

A

Virology

Studies of viral and host factors, including studies of replication in vitro, host restriction factors, viral life cycle, entry, tropism, and early and late viral phenotypes

B

Molecular Epidemiology and HIV/SIV Evolution

Studies of molecular epidemiology and HIV/SIV evolution, including simian reservoirs, transmission clusters, dual infections, subtype, and within patient diversity/compartmentalization

C

Pathogenesis: Human Studies and Animal Models

Studies of factors influencing disease outcome in humans and animal models, including HIV-host interactions, immune activation, host cell targets, cell compartments, genotype (viral and host) and disease, immune restoration, and mucosal factors

D

Host Immune Responses to Infection, Vaccines, and Immunotherapy

Studies of B- and T-cell responses to viral infection, vaccines, immune modulation (eg, cytokine interventions)

E

HIV Reservoirs, Latency, and All Curative Strategies Including Therapeutic Vaccines and Gene Therapy

Studies of all aspects, including human and animal studies, related to these topics

F

Neuropathogenesis and CNS HIV Complications

Studies of all aspects of neuropathogenesis, including neuroimmunity, neurodegeneration, virology of the CNS compartment (HIV entry, tropism, evolution, reservoir), CNS complications of systemic HIV infection and associated factors/responses, cerebrovascular complications (in conjunction with the Cardiovascular Complications clinical group), and biomarkers (including neuroimaging)

G

Clinical Pharmacology

All studies of the pharmacokinetics and pharmacodynamics (PK/PD) in animal models and humans, including studies of drug ADME, novel dosing regimens, drug interactions, and experimental/clinical therapeutics.  Includes pharmacologic modeling

H

Antiretroviral Therapy: Pre-Clinical and Randomized Trials

Studies of antiviral activity (all phases), including antiretroviral strategies, new agents, and combinations

I

Antiretroviral Therapy: Efficacy and Effectiveness Studies

Observational and cohort studies where the focus is on antiretroviral therapy and antiretroviral treatment strategies

J

HIV Drug Resistance

Studies of molecular mechanisms, pathogenesis, clinical implications, epidemiology, and resistance diagnostics

K

HIV Diagnostics

Studies of HIV diagnostic tests and their technical performance characteristics. Studies applying new HIV diagnostics in populations should be submitted to category W: Epidemiology. Studies of new technologies related to HIV drug resistance, complications, TB, other opportunistic infections, hepatitis, or malignancies should be submitted to those specific categories

L

Hepatitis Viruses and Liver Complications

Studies of the diagnostics, epidemiology of, pathogenesis of, and therapy for viral Hepatitis (including A, B, C, and E in monoinfection or HIV coinfection) and liver complications

M

Malignancies

Studies on the epidemiology, pathobiology, prognostic biomarkers, incidence, treatment and prevention approaches for malignancies or premalignant lesions in patients with HIV

N

Cardiovascular Complications of HIV Infection and Antiretroviral Therapy

Includes coronary, cardiac, and cerebrovascular complications, lipids, and peripheral vascular atheromatous disease

O

Other Complications of HIV Infection and Antiretroviral Therapy

Studies of renal, bone, metabolic, and other complications

P

Tuberculosis and Other Opportunistic Infections

Basic and clinical examination of bacterial, fungal, parasitic, and non-hepatitis viral infections

Q

Maternal/Fetal HIV

Studies of  maternal-fetal transmission (risks, mechanisms, and approaches to prevention) and early infant diagnosis

R

Pediatrics and Adolescents

Studies of HIV in infants, children and adolescents including HIV-exposed, uninfected children

S

Epidemiology

Risk factors for acquisition/transmission, cohort studies, incidence/prevalence, morbidity/mortality, HIV testing, surveillance, transmission clusters

T

Prevention Interventions

Preclinical and clinical studies of microbicides, pre- and post-exposure prophylaxis, treatment as prevention, medical male circumcision, and other prevention interventions

U

Prevention Scale-up

Implementation of prevention strategies for HIV uninfected populations, and studies in which HIV incidence is the primary outcome

V

Contraceptive and Reproductive Health in Women

Studies of the impact of contraceptive methods on HIV infection or disease, gynecologic malignancies, HPV screening, sexual health, sexually transmitted infections, and treatment of pregnant women for conditions other than pregnancy. Does not include studies on HIV epidemiology, prevention and treatment for women; these should be included in their respective categories.

W

Implementation and Scale-up of Treatment and Care

Including cascades, financing of care, population-level impact of treatment and care on health outcomes of persons living with HIV

X

Population and Cost Modeling

Includes research on demography, population impact, modeling and cost-effectiveness.  Does not include pharmacologic modeling (submit to Clinical Pharmacology) or basic science modeling (submit to the appropriate basic science category)

Y

Emerging Viruses: Zika Virus

All Studies of the Zika Virus